EP1021168A1 - Dispositif d'administration de microparticules ou de nanoparticules de polymeres - Google Patents

Dispositif d'administration de microparticules ou de nanoparticules de polymeres

Info

Publication number
EP1021168A1
EP1021168A1 EP98952243A EP98952243A EP1021168A1 EP 1021168 A1 EP1021168 A1 EP 1021168A1 EP 98952243 A EP98952243 A EP 98952243A EP 98952243 A EP98952243 A EP 98952243A EP 1021168 A1 EP1021168 A1 EP 1021168A1
Authority
EP
European Patent Office
Prior art keywords
particles
solution
polymers
corona
polyanionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98952243A
Other languages
German (de)
English (en)
Other versions
EP1021168A4 (fr
Inventor
Ales Prokop
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP1021168A1 publication Critical patent/EP1021168A1/fr
Publication of EP1021168A4 publication Critical patent/EP1021168A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Definitions

  • the present invention relates generally to the fields of pharmaceutical sciences, protein chemistry, polymer chemistry, colloid chemistry, immunology, and biomedical engineering. More specifically, the present invention relates to a novel microparticulate and nanoparticulate system for drug and antigen delivery, for gene (plasmid DNA) delivery and antisense RNA an d DNA oligonucleotide delivery.
  • Microparticulate systems are solid particles having a diameter of 1-2,000 ⁇ m (2 mm) and more preferably 1-10 ⁇ m (microparticles).
  • Both microparticles an d nanoparticles can be formed from variety of materials, including synthetic polymers and biopolymers (proteins an d polysaccharides). Both microparticles and nanoparticles are u s ed as carriers for drugs and other biotechnology products, such a s antigens, genes and antisense oligonucleotides.
  • microparticles and nanoparticles are formed in a mixture with molecules to be encapsulated within the particles, for subsequent sustained release.
  • a number of different techniques are routinely used to make these particles from synthetic or natural polymers, including phase separation, precipitation, solvent evaporation, emulsification, and spray drying, or a combination of thereof [Desay, P.B., Microencapsulation of drugs by pan and air suspension technique. Crit. Rev. Therapeut. Drug Carrier Syst., 5 : 99-139 (1988); Berthold, A., Cremer, K., Kreuter, J.
  • Microparticles and nanoparticles can be prep ared either from preformed polymers, such as polylactic acid, polylactic-glycolic acid [Cohen, et al., Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres . Pharm. Res. 8: 713-720 (1991)], or from a monomer during its polymerization, as is the case of polyalkylcyanoacrylates [Al- Khouri-Fallouh, et al., Development of new process for th e manufacture of polyisobutylcyanoacrylate nanoparticles. Int. J. Pharm. 28: 125-132 (1986)].
  • preformed polymers such as polylactic acid, polylactic-glycolic acid [Cohen, et al., Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres . Pharm. Res. 8: 713-720 (1991)]
  • polyalkylcyanoacrylates Al- K
  • microparticles and nanoparticles are related technology which has been also explored for the purpose of making microparticles and nanoparticles.
  • Such particles can be formed either by polymer precipitation, following the addition of a non-solvent or by gelling, following the addition of a small inorganic ion (salt) and of a complexing polymer (of a n opposite charge). If enough time is allowed, the particle interior (core) can be completely gelled.
  • the inner core material is typically of a polyanionic nature (negatively charged polymer)
  • the particle membrane (corona) is made from a combination of polycation (positively charged polymer) and polyanion.
  • the core material is usually atomized (nebulized) into small droplets an d collected in a receiving bath containing a polycationic polymer solution.
  • th e core material is polycationic and the receiving bath is polyanionic.
  • the prior art is deficient in the lack of effective means of drug and antigen delivery, as well as plasmid and oligonucleotide delivery.
  • the present invention fulfills this longstanding need and desire in the art.
  • th e present invention provides new combinations of multicomponent water-soluble polymers which allow for modification of th e particle size down to a desirable size, adequate mechanical strength, and desirable permeability and surface characteristics.
  • the present invention provides a method of preparing of microparticles and nanoparticles by means of a hollow ultrasonic device and a combination of polymers a t relatively low concentrations.
  • the present invention provides a method of production of micro- a n d nanoparticles in a single step process.
  • th e present invention provides a composition of matter of micro- an d nanoparticles whereas the multicomponent combination of polymers is composed of a structural (gelling) polymer and a polymer providing the mechanical strength (crosslinking) and permeability control.
  • the present invention provides a composition of matter and method of incorporation of antigens as an integral part of the particulate matter.
  • the present invention provides a composition of m atter and method of electrostatic and steric stabilization of particles whereas the stabilizing polymers are integral part of th e particulate matter. Also provided is a method of direct use of particles generated in the single step as a vaccine delivered orally, nasally, rectally or vaginally, through inhalation to the lung, an d by injection into muscle or skin or underneath the skin.
  • the present invention provides a composition of matter and method of production whereas th e particles comprise of anionic DNA or oligonucleotide incorporated as an integral part of the matter. Further provided is a method of post-production processing of particles, composed of recovery an d washing steps.
  • the present invention provides a method of stabilization and composition of matter of particles by means of physiological crosslinking agents. Also provided is a method of cryoprotection and stabilization by means of lyophilization.
  • the present invention provides methods of adjustment of biodegradation and composition of matter of particles by means of incorporation of suitable enzymes degrading polysaccharides, a method of immunization by means of oral, nasal, rectal or vaginal delivery of particles, by inhalation to the lung, and injection into muscle or skin or underneath the skin, a method of introduction of alum adjuvant as an integral part of particles and composition of matter, method of incorporation of mucoadhesive polymers into the particles and compositions.
  • the present invention provides a method of making particles useful in, for example, drug delivery, comprising the steps of: providing a stream of uniformly-sized submicron or few micron drops of polyanionic polymer solution by means of a hollow ultrasonic device; collecting said droplets in a stirred reactor provided with a cationic solution; wherein the polyanionic droplets and said cationic solution react to form particles.
  • the particles have a polyanionic core an d poly anionic/poly cationic complex shell (corona) with excess of th e positive charge on the particle periphery.
  • a stream of cationic solution of the size is collected in a polyanionic solution.
  • the particles have polycationic core and polycationic/polyanionic complex shell (corona) with the excess of negative charge on th e particle periphery.
  • the polyanionic and polycationic solutions are mixed together in the ratio of 1 : 1 to 1 :4 (the s ame ratio of polycationic to polyanionic solutions in the converse mode) and gently stirred for 5-10 minutes.
  • a spontaneous formation of particles is observed.
  • streams of uniformly sized submicron droplets of both polyanionic and polycationic solutions are reacted in a gas- phase reactor.
  • composition of matter comprising new multicomponent systems to generate microparticles, composed of a structural (gelling) polymer and a polymer providing the mechanical strength and permeability control.
  • an embodiment may be where th e individual components of the core polyanionic solution of polymers include concentrations of 0.01 wt-% to 0.5 wt-%.
  • a more preferred embodiment would include a composition, where each component of the polyanions is at a concentration of 0.05 wt-% to 0.2 wt-%.
  • the individual components of the corona cationic solution are at a concentration of 0.01 wt-% to 0.5 wt-%.
  • the polycations are at 0.05 wt-% to 0.2 wt-% and calcium chloride at 0.05 wt-% to 0.2 wt-% ( and potassium chloride at 0.05 wt-% to 0.2 wt-% in case carrageenans are used as anionic polymers).
  • a composition of matter comprising of the core polymers and cationic antigens, the latter being incorporated as an integral part of the ionically formed complex.
  • th e individual components of the core cationic solution of polymers and inorganic salts include concentrations of 0.01 wt-% to 0.5 w t - %.
  • a more preferred embodiment would include a composition, where each component of the polycations and of inorganic salts is at a concentration of 0.05 wt-% to 0.2 wt-%.
  • th e individual components of the corona polyanionic solution are at a concentration of 0.01 wt-% to 0.5 wt-%.
  • the polycations are at 0.05 wt-% to 0.2 wt-%.
  • the present invention may include th e composition of matter comprising of charged polymeric surface modifiers (electrostatic stabilizers), the latter being incorporated in one step together with other polymeric components as a n integral part of the complex.
  • a nonionic polymeric surface modifier (steric stabilizer) is integrated into the polymer structure via an entrapment. Both classes of surface modifiers are included to prevent particle aggregation upon their further processing.
  • a method of direct use of the said reactor content in th e case of oral, nasal, rectal, and vaginal application (vaccine), application by inhalation to the lung, and injection into muscle or skin or underneath the skin.
  • Another aspect of the present invention provides a composition of matter comprising of anionic polymers and anionic antigens (and plasmid DNA and antisense RNA and DNA oligonucleotide), the latter being incorporated as a n integral part of the ionically formed complex.
  • the present invention includes a method of processing of said reactor content comprising the steps of: sedimenting or centrifuging said reactor mixture; collecting microparticles or nanoparticles as a pellet; rinsing said particles in a large excess of water, buffer, cryopreservation solution, electrostatic or steric stabilizer solution; separating said suspension by said sedimentation or centrifugation step; repeating said rinsing and separation steps; and reducing volume of the said suspension to about 1/lOOth of the initial volume.
  • th ere is provided a method of a chemical stabilization of the washed an d isolated particles comprising the steps of: reacting the particles with a crosslinking agent; rinsing said particles in a large excess of water, buffer or a cryopreservation solution, electrostatic or steric stabilizer solution; separating the particles via sedimentation o r centrifugation; repeating the rinsing and separation steps; and reducing volume of the suspension.
  • the crosslinking agent is dextran polyaldehyde, a solution of photocrosslinking polymer, or a ⁇ -glutamyl transferase enzyme. The reaction conditions are selected accordingly, bu t within the physiological realm.
  • the present invention may include a method of cryoprotecting said washed particles comprising th e steps of: suspending the particles in a cryoprotective solution; and lyophilization of the suspension in a suitable lyophilization apparatus.
  • a preferred embodiment would include glycerol, sucrose, PEG, PPG, PVP, block polymers of poly oxy ethylene an d polyoxypropylene, water soluble derivatized celluloses and some other agents at a concentration of 1 wt-% to 10 wt-%.
  • a method of adjustment of biodegradability of polymeric mixtures comprising the steps of: adding a suitable amount of suitable enzyme to a polysaccharide to be degraded; breaking down a polysaccharide at physiological conditions in vivo to degradation products which can be further broken to nonharmful products in animal/human body.
  • a preferred embodiment would include alginate-lyase (alginase) and carrageenase for polymer matrices containing alginate or carrageenans, in quantities allowing for controlled biodegradation in the range of one week to several months.
  • alginate-lyase alginase
  • carrageenase for polymer matrices containing alginate or carrageenans, in quantities allowing for controlled biodegradation in the range of one week to several months.
  • a method of introducing an adjuvant to potentiate a n immunogenic effect is preferably aluminum salt enabling to gel certain polysaccharides.
  • the preferred embodiment could include CMC, CS and HV alginate as droplet forming anionic polymers, either individually, or in a mixture, and aluminum sulfate (or any other water soluble aluminum salt), calcium chloride and a suitable polycationic polymers as a corona forming mixture.
  • a method of adding mucoadhesive polymers to the corona-forming bath to provide for sticking properties in relation to mucosal areas in animal/human body.
  • Figure 1 shows the size distribution of nanoparticles with an integrated OVA immunogen.
  • Figure 2 shows the charge distribution of nanoparticles with an integrated OVA immunogen.
  • Figure 3 depicts the response to subcutaneous nanoparticulate OVA antigen (second column) in terms of anti- OVA antibodies. The bars represent the average +/- SD.
  • Figure 4 depicts the response to subcutaneous nanoparticulate TT antigen (second column) in terms of anti-TT antibodies. The bars represent the average +/- SD.
  • Figure 5 depicts the response to an oral nanoparticulate OVA antigen (second column) in terms of the total serum anti-OVA antibodies at day 21. The bars represent the average +/- SD.
  • OVA-SOL represents the oral application of soluble antigen;
  • OVA/NP-ORL nanoparticulate formulation and NP- ORL are empty nanoparticles (no OVA).
  • Figure 6 demonstrates in vivo gene expression.
  • DNA-ID represents intradermal injection of naked DNA solution (plasmid); Lipofect/DNA is DNA complexed with Lipofectamine reagent (Gibco, Gaithersburg, MD); and NP/DNA is DNA encapsulated in nanoparticles.
  • the term “reactor” shall refer to a n enclosed vessel provided with or without a stirrer, allowing for a reaction to proceed in liquid or gas phases.
  • the term “insoluble submicronic particles” shall refer to particles which remain solid in essentially water-based solutions, such as water, saline, PBS or a physiological buffer.
  • the term “light scattering (Tyndall effect)” shall refer to light dispersion in many directions, resulting in a slightly milky suspension, visible by a human eye.
  • the term “ultrasonic probe” shall refer to a hollow metallic tube whose tip oscillates many cycles per second as directed by a power imposed upon it.
  • nanoparticle shall refer to submicroscopic (less than 1 micrometer in size) solid object, essentially of regular or semi-regular shape.
  • corona shall refer to an insoluble polymeric electrostatic complex composed of internal core polymer(s) an d receiving bath polymer(s) molecularly bound in a close proximity.
  • structural (gelling) polymer shall refer to polymers which can form semi-solid gelled structure by mean s of a small ion complexing.
  • core polymer shall refer to a drop-forming polymer which represents an internal (central) part of the nanoparticle.
  • th e term “charged polymeric surface modifiers (electrostatic stabilizers)” shall refer to a poly electrolyte (polymer) exhibiting a high charge density and as such providing the particle periphery with a high surface charge density, allowing for a strong repulsion force between adjoining particles.
  • th e term “nonionic polymeric surface modifier (steric stabilizer)” shall refer to nonionic (without charge) polymers with protruding side chains residing on the particle periphery and preventing intimate contact between adjoining particles.
  • the term “cryoprotecting” shall refer to substances used for suspension of particles, which upon their water removal in vacuum allow particles to remain in individual and nonaggregating state
  • SA-HV high viscosity sodium alginate
  • CS cellulose sulfate
  • k-carr kappa carrageenan
  • LE-PE low-esterified pectin (polygalacturonic acid)
  • PGA polyglutamic acid
  • CMC carboxymethylcellulose
  • ChS-6 chondroitin sulfate-6
  • ChS-4 chondroitin sulfate-4
  • F-68 Pluronic copolymer
  • GGT ⁇ -glutamyl transferase
  • DPA dextran polyaldehyde
  • PVSA polyvinylsulphonic acid
  • PVPA polyvinyl phosphonic acid
  • PAA polyacrylic acid
  • PVA polyvinylamine
  • OVA ovalbumin
  • C-OVA cationized ovalbumin
  • BSA bovine s eru m albumin
  • AG acacia gum
  • the present invention is directed to a composition of matter comprising various poly anion and polycation mixtures.
  • a particularly usable combination is a combination of anionically charged antigen (or plasmid DNA or antisense oligonucleotide)/ SA-HV/CS and SP/PMCG/CaCl 2 .
  • It is specifically contemplated th at pharmaceutical compositions may be prepared using a drug, o r antigen, or plasmid DNA, or an antisense RNA oligonucleotide, encapsulated in the particles of the present invention.
  • the pharmaceutical composition may comprise a drug (or other biotechnology product) and a biologically acceptable matrix.
  • th e appropriate concentrations of said biotechnology products, matrix composition and routes of administration of the particles of th e present invention.
  • the present invention provides methods for making particles, for their further surface modification, crosslinking and cryopreservation, and for an application of th e encapsulated biotechnology products (drugs, plasmid DNA, antisense oligonucleotide), and for the immunization of an animal using encapsulated antigen.
  • the present invention is a water-based technology.
  • Resulting particles consist of a dense polymeric core matrix, i n which a drug (or antigen; plasmid DNA; antisense nucleotide) can be dispersed or dissolved, surrounded by a polymeric shell (corona).
  • a drug or antigen; plasmid DNA; antisense nucleotide
  • corona a polymeric shell
  • a typical problem is a use of organic solvents for manufacturing particles, rather loose association of plasmid DNA within a liposome [Sternberg, et al., New structures in complex formation between DNA and cationic liposomes visualized b y freeze-fracture electron microscopy. FEBS Letters 356: 361 - 366 (1994)] or a low stability of the DNA-spermine complex a t physiological conditions [Milson, R.W., Bloomfield, V.A. Counterion- induced condensation of DNA. A light-scattering study . Biochemistry 18: 2192-2196 (1979)] .
  • liposomes exhibit a very low incorporation of highly hydrophilic substances, such as DNA or polynucleotide.
  • th e present invention provides a multicomponent particle formed b y polyelectrolyte complexation.
  • the drug or targeted biological substance is polyelectrolyte by virtue of its nature, such components become an integral part of the particle.
  • This n e w micro- and nanoparticulate technology has been applied as a vehicle for oral delivery of antigen, leading to subsequent immunization in vivo.
  • Particles may be made in a stirred reactor.
  • a reactor is filled with a cationic solution.
  • a mist of anionic droplets were generated by means of a hollow ultrasonic probe and introduced into the cationic solution residing in the reactor or receiving bath.
  • 1-2 ml of anionic solution is extruded into 20 ml of cationic solution in a batch mode, resulting in a nonstoichiometric complex with an excess of cationic charge on the particle periphery.
  • Instantly, insoluble submicronic particles are formed as evidenced by a light scattering (Tyndall effect).
  • the reaction time can be adjusted.
  • 1-2 hours is sufficient for particle maturation. This is due to their thermodynamic instability, large surface area and surface free energy.
  • the size can be measured by means of a Malvern ZetaMaster (Malvern, UK).
  • composition and combinations of anionic polymer mixture as well of the cationic receiving bath is essential to allow for adjustments in particle size, shape and uniformity.
  • droplets can be made from polycationic solution and the receiving bath contains then a polyanionic solution.
  • th e polyanionic and polycationic solutions are mixed together in th e ratio of 1 : 1 to 1 :4 (the same ratio of polycationic to polyanionic solutions in the converse mode) and gently stirred for 5 - 1 0 minutes (without the employment of the ultrasonic probe). For many combinations of polymers, a spontaneous formation of particles is observed.
  • a continuous flow reactor system was constructed, composed of a continuous stream of submicron size drops of the core polyanionic solution, by means of a hollow ultrasonic device and a continuous stirred reactor filled with a corona cationic solution and provided with an inflow and outflow of this solution.
  • the core solution is continuously introduced into the corona solution; the ratio of droplet (core)- to corona-forming solution flow rates is adjusted to result a nonstoichiometric polymeric complex. It is typically 1 :20 to 3:20.
  • PAA/gellan Chit/calcium chloride PAA/ ⁇ -carr Chit/calcium chloride EXAMPLE 3
  • This particle was generated using a droplet-forming polyanionic solution composed of 0.1 wt-% HV sodium alginate (SA-HV) and 0.05 wt-% chondroitin sulfate C (ChS-C) in water an d corona-forming polycationic solution composed of 0.1 wt-% spermine hydrochloride (SH), 0.01 wt-% poly-L-lysine hydrochloride (PLL) and 0.2 wt-% calcium chloride in water.
  • the chemicals used were: high viscosity sodium alginate (SA-HV) from Kelco/Merck (San Diego, CA) of average molecular weight 4.6 x
  • chondroitin sulfate-6 (ChS-6) from Sigma (St. Louis, MO); spermine hydrochloride (SH); poly-L-lysine (PLL), of average molecular weight 4.5 x 10 , and calcium chloride.
  • the ratio of droplet- to corona-forming reactants was 1.0:20.
  • the particles were instantaneously formed in a batch system, allowed to react for 2 hours and their size and charge evaluated in the reaction mixture. The average size was 280 nm and the average charge 20.1 mV. Particles remained stable as individual entities during four week period at 4°C. The size of particles tended to increase upon their processing (washing in saline or water), if no t stabilized.
  • Nanoparticle 2 This particle was generated using a droplet-forming polyanionic solution composed of 0.1 wt-% HV sodium alginate (SA-HV) and 0.1 wt-% CS in water and corona-forming polycationic solution composed of 0.1 wt-% PMCG hydrochloride, and 0.2 wt-% calcium chloride in water.
  • the polymers used were : cellulose sulfate, sodium salt (CS) from Janssen Chimica (Geel,
  • the polymers used were : acacia gum (AG) from Sigma, average molecular weight 4.5 x 10 ⁇ isoelectric point (pi) 4.0; egg ovalbumin (OVA) from Sigma, average molecular weight 4.2 x 10 ⁇ , pi 4.6; and bovine s erum albumin (BSA) from Sigma, with average molecular weight 6.7 x 10 , pi 5.4.
  • AG acacia gum
  • OVA egg ovalbumin
  • BSA bovine s erum albumin
  • the polymers used were: chitosan glutamate Protasan HV (Chit) from Pronova Biopolymers (Drammen, Norway), average molecular weight 7.5 x 10 ⁇ ; cationized ovalbumin (C-OVA), synthesized in-house according to published procedure [Altmann,
  • Particles were separated as in Examples 4 and 5. Average size was 390 nm and average charge 15.9 mV. After a 2 hour maturation time, particles were centrifuged at 15°C for 1 5 minutes at 10,000g in a refrigerated Beckman centrifuge L5 -50 (Beckman Instruments, Fullerton, CA). Next, the supernatant w as carefully aspirated off by means of pipette without disturbing th e layer of particles at the bottom of 35 ml centrifuge tubes. The sediment was then resuspended in 1 ml water by repeated pipetting in and out, tubes filled up to 35 ml with water a n d centrifuged again. After removing the supernatant, a dense suspension of particles (1 ml) was evaluated for size and charge. The average size was 450 nm and average charge +10.2 mV (at pH 6.8).
  • particles were prepared as above but the droplet-forming solution contained an additional polymer, PDA.
  • concentrations used were 0.00014 wt-%, 0.0007 wt-% and 0.0014 wt-%.
  • a portion of particles was incubated in a Tris buffer (pH 1.85) for 1.5 hour and released protein (TT) w as assayed in the supernatant by means of the Pierce method (Table III).
  • the average exposure time 1.5 hours represents , approximately, the residence time of particles in the stomachs of experimental animals.
  • Particles were prepared as in Example 5. First, th ey were separated by centrifugation at 10,000 x g and then rinsed in water and resuspended in a solution containing a cryoprotective agent. A concentrated suspension of particles was then frozen in a mixture of ethanol-dry ice and lyophilized thereafter using a lyophilization apparatus (The Virtis Co., Gardiner, NY), under a vacuum. In this case, only two cryoprotective agents were tested on two portions of particulate suspension: 2 wt-% PEG (Sigma, average molecular weight 8 x 10 ⁇ , and 2 wt-% HEC (Scientific Polymers Products). The resulting product was particulate an d easily resuspendable in water. The average size of particles increased from the original 425 nm to 625 nm, or 450 nm to 590 nm, respectively.
  • Particles were prepared as in Example 1, except that the core polymeric mixture was adjusted to allow for a slow degradation when applied in vivo.
  • a purified alginase-lyase (alginase) was obtained courtesy of N.L. Schiller [Schiller, et al., Characterization of the Pseudomonas aeruginosa alginate lyase gene (algL): Cloning, sequencing, and expression in Escherichia coli. f. Bacteriology 175: 4780-4789 (1993)] and used at levels of 1 a n d 10 ⁇ g/L in the core solution. Particles were prepared, washed in
  • Example 11 Particles were prepared as in Example 11 , stabilized by cross-linking with PDA, as specified in Example 12 (PDA concentration used was 0.001 wt-%), and applied subcutaneously in animals, as specified in Example 9. Results were similar to those reported in Example 9.
  • Total serum anti-OVA antibody titers ar e presented in Figure 3.
  • OVA-SQ represents the application of soluble antigen OVA
  • OVA/NP-SQ a subcutaneous application of nanoparticles loaded with OVA
  • NP-SQ a subcutaneous application of empty (no OVA) nanoparticles (negative control)
  • CRL-1005 Vaxcel, Norcross, GA
  • OVA-SQ formulated with help of a polymeric adjuvant similar to those mentioned in Example 8.
  • Nanoparticles were generated using droplet-forming polyanionic mixture composed of 0.1 wt-% CMC and 0.05 wt-% CS in water and corona-forming polycationic mixture composed of 0.2 wt-% aluminum sulfate and 0.1 wt-% PMCG in water.
  • Chemicals used were: aluminum sulfate (Sigma) and carboxymethylcellulose (brand 7MF, CMC, Aqualon/Hercules, Wilmington, DE), having medium molecular weight.
  • Aluminum sulfate was incorporated into the nanoparticles as it is known to potentiate antigenic response [Cox, J.C., Coulter, A.R., Adjuvants - a classification an d review of their modes of action, Vaccine 15 :248-256 ( 1997)] .
  • This plasmid was expressed in a bacterium, grown in a culture and isolated in-house.
  • the ratio of droplet- to corona-forming reactants was 1 : 10.
  • a special glass double-nozzle atomizer was used for particle generation.
  • the droplet-forming solution was applied in the internal nozzle, while the air was used to strip particles off the internal nozzle and atomize them into submicron-range size using an internal nozzle.
  • the droplets were then collected in the corona-forming solution.
  • Such device was used because the DNA molecule is sensitive to sonication and can be substantially damaged.
  • the particles w ere separated by centrifugation and washed. Their size and charge were 190 nm and +24.0 mV, respectively. These particles exhibited an expression of luciferase enzyme in several in vitro cell culture lines.
  • nanoparticles with integrated cationic drug are prepared by a reverse encapsulation, similar to Example 6.
  • capsules were prepared by means of a n atomization technique. Capsules were of an average size of 350 ⁇ m and capsule chemistry was similar to that of Example 4. To measure a release rate, capsules were equilibrated with a tracer solution overnight. A capsule pellet (0.5 ml) was then placed in 5 ml test buffer (PBS) on a shaker and successive aliquots w ere taken and analyzed. The tracer quantity was assayed using th e methods described below. Insulin (Sigma) and OVA were used a s tracers.
  • Insulin was assayed by a RIA method by means of Coat- A-Count Insulin Detection Kit (diagnostic Products Corp., Los Angeles, CA) and OVA by a protein assay (Bradford) method (Bio- Rad, Hercules, CA). The permeability was assessed via an efflux method [11]. Results are listed in Table V. As shown in Table V, permeability can be controlled by means of cation concentration (PMCG, calcium chloride) and by reaction time.
  • PMCG cation concentration
  • the outer particulate surface has mucoadhesive properties .
  • Many polymers listed for multicomponent systems are believed to be mucoadhesive (heparin, ChS-4, ChS-6, carrageenans, xanthan, gellan, pectin, gelatin, CS, CMC, chitosan).
  • other polymers can be considered (crosslinked PAA, polymethacrylic acid, hyaluronic acid and collagen).
  • uncharged polymers can be incorporated (as an additional component) into the multicationic component (corona) system : HPC, HEC, scleroglucan (SG), polyhydroxymethacrylate (pHEMA), PVP, PVA, PEO, PEG and copolymers of the above.
  • HPC high C
  • HEC scleroglucan
  • pHEMA polyhydroxymethacrylate
  • PVP polyvinyl
  • PVA polyvinyl
  • PEO polyethylene glycol
  • copolymers of the above.
  • the listed polymers can be used as mucoadhesive polymers as well a s polymers exhibiting steric surface stabilization effect (Example 8) .
  • Some special substances can also be added to the list: mussel adhesive protein, plant and bacterial lectins and other specialty mucoadhesive polymers.
  • mucoadhesive polymers can be u s ed in the corona forming mixture in the range of 0.01 to 0.2 wt% in the receiving bath.
  • the mucoadhesive polymers become integral part of the micro- and nanoparticulate system a t processing.
  • the average size and charge were evaluated to be 210 nm and 35.1 mV, respectively.
  • the nanoparticles were then introduced orally into the experimental mice (C57B 1/6, Harlan, Indianapolis, IN). The immunizations were carried at day 0, 7 and 14. At day 21 , blood was collected and assayed for the total serum anti-OVA antibodies. Results ar e summarized in Figure 5. The immunizations with OVA- nanoparticles resulted in greater levels of serum antibodies th an those found with soluble antigen.
  • Each animal had 2 negative controls (5 wt-% glucose) and two positive controls (5 wt-% glucose, 0.025 wt-% Lipofectamine, 0.025 wt-% pCEPluc plasmid). Animals w ere harvested after 24 hours by means of 8 mm skin punch. Gene expression was measured by assaying for luciferase activity in minced and permeabilized cell extracts, using a luminometer an d data were normalized per protein content. The commercial luciferase assay kit (Sigma) was used. In another set of experiments, empty nanoparticles were used as another negative control with values of RLU/protein close to the negative control.
  • Results are presented in Figure 5.
  • Similar results were obtained for polyanionic solution containing 0.025 wt-% pCEPluc and 0.005 wt-% SA-HV and polycationic solution containing 0.05 wt-% Tetronic 904 and 0.005 wt-% CaC12 in water.
  • Some other detergents of the Pluronic and Tetronic series (BASF) worked equally well.

Abstract

L'invention concerne un procédé de fabrication de particules utile pour l'administration de médicaments. Le procédé consiste à mettre en contact des polymères polyanioniques et des cations dans un réacteur à agitation, et de provoquer une réaction des polyanions et des cations pour former des particules.
EP98952243A 1997-10-09 1998-10-09 Dispositif d'administration de microparticules ou de nanoparticules de polymeres Withdrawn EP1021168A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6294397P 1997-10-09 1997-10-09
US62943P 1997-10-09
PCT/US1998/021455 WO1999018934A1 (fr) 1997-10-09 1998-10-09 Dispositif d'administration de microparticules ou de nanoparticules de polymeres

Publications (2)

Publication Number Publication Date
EP1021168A1 true EP1021168A1 (fr) 2000-07-26
EP1021168A4 EP1021168A4 (fr) 2006-08-30

Family

ID=22045878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98952243A Withdrawn EP1021168A4 (fr) 1997-10-09 1998-10-09 Dispositif d'administration de microparticules ou de nanoparticules de polymeres

Country Status (3)

Country Link
EP (1) EP1021168A4 (fr)
AU (1) AU9799198A (fr)
WO (1) WO1999018934A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19810965A1 (de) * 1998-03-13 1999-09-16 Aventis Res & Tech Gmbh & Co Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung
AU1186401A (en) 1999-06-23 2001-01-22 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
WO2001047501A1 (fr) * 1999-12-29 2001-07-05 Nanodelivery, Inc. Systeme de distribution de medicament a regulation de permeabilite
EP1443912B1 (fr) * 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions combinant des caracteristiques de liberation immediate et de liberation prolongee
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
ES2226567B1 (es) * 2003-06-20 2006-07-01 Universidad De Santiago De Compostela Nanoparticulas de acido hialuronico.
ES2246695B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico.
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
KR100604976B1 (ko) * 2004-09-03 2006-07-28 학교법인연세대학교 다작용기 리간드로 안정화된 수용성 나노입자
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
WO2006091180A2 (fr) * 2005-02-25 2006-08-31 Ali Demir Sezer Systemes vecteurs du medicament multiparticulaire fucoidane
WO2006101706A1 (fr) * 2005-03-17 2006-09-28 Cargill, Incorporated Compositions liquides pour applications liees a la sante
US8303931B2 (en) 2006-02-17 2012-11-06 Topass Gmbh Multimodal imaging using a three compartment polymer nanoparticle with cell specificity
JP2009539793A (ja) * 2006-06-08 2009-11-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 診断及び治療用途のための官能化された固体ポリマーナノ粒子
AU2007319701A1 (en) * 2006-08-17 2008-05-22 Novartis Ag Nanoparticle compositions
EP2070521A1 (fr) * 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanoparticules à surface modifiée
DE102007059752A1 (de) * 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
ES2341165B2 (es) * 2008-10-28 2010-10-27 Universidad De Santiago De Compostela Nanoparticulas de acido colominico y derivados.
ES2342588B2 (es) * 2008-10-28 2011-03-10 Universidade De Santiago De Compostela Sistemas nanoparticulares elaborados a base de polimeros anionicos.
WO2010049562A1 (fr) * 2008-10-28 2010-05-06 Universidade De Santiago De Compostela Systèmes nanoparticulaires élaborés à base de polymères anioniques
ES2345806B1 (es) * 2009-03-30 2011-07-22 Universidad De Santiago De Compostela Sistemas nanoparticulares elaborados a base de polimeros anionicos para administrar moleculas bioactivas para uso cosmetico.
WO2010100781A1 (fr) * 2009-03-06 2010-09-10 国立大学法人東京大学 Composition pour l'administration d'acide nucléique
MX2021010105A (es) 2016-06-01 2022-06-16 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
EP3471705A1 (fr) * 2016-06-20 2019-04-24 Virbac Procédé et appareil destinés à préparer une composition de microparticules
CN113171355B (zh) * 2021-04-25 2022-07-19 华中农业大学 具有m细胞靶向的硫酸黏杆菌素自组装纳米颗粒、制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454044A2 (fr) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Produit pharmacologique contenant des composés de polyélectrolytes sous forme de microparticules et au moins un agent actif

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454044A2 (fr) * 1990-04-25 1991-10-30 Hoechst Aktiengesellschaft Produit pharmacologique contenant des composés de polyélectrolytes sous forme de microparticules et au moins un agent actif

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9918934A1 *
TAYLOR WANG ET AL.: "An encapsulation system for the immunoisolation of pancreatic islets" NATURE BIOTECHNOLOGY., vol. 15, no. 4, 1997, pages 358-362, XP008066998 USNATURE PUBLISHING GROUP, NEW YORK, NY. *

Also Published As

Publication number Publication date
EP1021168A4 (fr) 2006-08-30
AU9799198A (en) 1999-05-03
WO1999018934A1 (fr) 1999-04-22

Similar Documents

Publication Publication Date Title
US6726934B1 (en) Micro-particulate and nano-particulate polymeric delivery system
WO1999018934A1 (fr) Dispositif d'administration de microparticules ou de nanoparticules de polymeres
Alonso Nanoparticulate drug carrier technology
Abedini et al. Overview on natural hydrophilic polysaccharide polymers in drug delivery
Janes et al. Polysaccharide colloidal particles as delivery systems for macromolecules
Basarkar et al. Preparation, characterization, cytotoxicity and transfection efficiency of poly (DL-lactide-co-glycolide) and poly (DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA
Abdelkader et al. Review on micro-encapsulation with chitosan for pharmaceuticals applications
Kumar Nano and microparticles as controlled drug delivery devices
Agnihotri et al. Recent advances on chitosan-based micro-and nanoparticles in drug delivery
Mitra et al. Chitosan microspheres in novel drug delivery systems
Prabaharan et al. Chitosan-based particles as controlled drug delivery systems
JP3887454B2 (ja) 重合体親水性ナノ粒子の製造方法
US5922357A (en) Polymer microspheres and a method of production thereof
US6156348A (en) Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5904936A (en) Particles based on polyamino acid(s) and capable of being used as delivery vehicles for active principle(s) and method for preparing them
US10172807B2 (en) Nanoparticle
Matalqah et al. Chitosan nanoparticles as a novel drug delivery system: a review article
Gupta et al. Optimization of process variables for the preparation of chitosan-alginate nanoparticles
US20030170313A1 (en) Micro-particulate and nano-particulate polymeric delivery system
JP2003519565A (ja) 重合体多層による固体粒子の鋳型化
IE20080211A1 (en) Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
US20040136961A1 (en) Nanoparticulate composition for efficient gene transfer
JP2004510729A (ja) 親水性活性成分（インスリン）を保持するためのサブミクロン粒子のコロイド懸濁液及びそれらの調製方法
Slomkowski et al. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery
Pacho et al. Synthesis of micro-and nanoparticles of alginate and chitosan for controlled release of drugs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20060801

17Q First examination report despatched

Effective date: 20070605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071016